Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion

As Novartis launches its self-administered multiple sclerosis drug Kesimpta, rival Roche has been looking for a convenience boost with its earlier-to-market blockbuster Ocrevus—and it just snagged a U.S. go-ahead toward that goal.